Goldman Sachs (GS) initiated coverage on Juno Therapeutics Inc. (JUNO) with a ‘Neutral’ rating and $52 price target in a research report issued to clients and investors on Tuesday. The name was also initiated with an ‘Overweight’ at JP Morgan (JPM) and a 12-month base case estimate of $66, and with an ‘Outperform’ at Leerink […] View the full post at: Trader’s Buzz: Juno Therapeutics Inc. (JUNO), Google Inc. (GOOG), Ocwen Financial Corp. (OCN) Related posts: SEC proposes identification for fast traders Nvidia Countersuing Rival Intel Corp. Google Finds Itself Under Increasing Antitrust Scrutiny